Robin Carson

3.1k total citations
33 papers, 258 citations indexed

About

Robin Carson is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Robin Carson has authored 33 papers receiving a total of 258 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 18 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Robin Carson's work include Multiple Myeloma Research and Treatments (29 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (8 papers). Robin Carson is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Peptidase Inhibition and Analysis (8 papers). Robin Carson collaborates with scholars based in United States, Spain and Netherlands. Robin Carson's co-authors include Pieter Sonneveld, María‐Victoria Mateos, Andrew Spencer, Tahamtan Ahmadi, Meral Beksaç, Meletios Α. Dimopoulos, Wendy Crist, Jodi Carey, Katja Weisel and Jesús F. San Miguel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Robin Carson

29 papers receiving 252 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Carson United States	10	204	160	138	36	28	33	258
Katia Mancuso Italy	8	240 1.2×	154 1.0×	162 1.2×	25 0.7×	23 0.8×	39	281
M. Mietzel United States	6	327 1.6×	182 1.1×	309 2.2×	25 0.7×	30 1.1×	19	414
Miguel Teodoro Hernández‐Garcia Spain	6	328 1.6×	168 1.1×	264 1.9×	39 1.1×	16 0.6×	10	373
Katarina Uttervall Sweden	8	202 1.0×	121 0.8×	122 0.9×	31 0.9×	28 1.0×	25	229
Serena Rocchi Italy	9	255 1.3×	157 1.0×	180 1.3×	33 0.9×	18 0.6×	31	301
Leah Fink Switzerland	8	379 1.9×	228 1.4×	277 2.0×	59 1.6×	8 0.3×	15	403
Evžen Gregora Czechia	11	253 1.2×	130 0.8×	218 1.6×	43 1.2×	9 0.3×	29	301
Xenofon Papanikolaou United States	7	241 1.2×	150 0.9×	167 1.2×	50 1.4×	8 0.3×	30	310
Abdul Rafae United States	8	133 0.7×	119 0.7×	84 0.6×	38 1.1×	33 1.2×	34	256
Paul Schoen United Kingdom	7	351 1.7×	208 1.3×	269 1.9×	54 1.5×	7 0.3×	9	380

Countries citing papers authored by Robin Carson

Since Specialization

Citations

This map shows the geographic impact of Robin Carson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Carson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Carson more than expected).

Fields of papers citing papers by Robin Carson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Carson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Carson. The network helps show where Robin Carson may publish in the future.

Co-authorship network of co-authors of Robin Carson

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Carson. A scholar is included among the top collaborators of Robin Carson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Carson. Robin Carson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fu, Weijun, Soo‐Mee Bang, Honghui Huang, et al.. (2025). Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study. Annals of Hematology. 104(5). 2765–2776. 1 indexed citations

Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations

Landgren, Ola, Ajai Chari, Yaël C. Cohen, et al.. (2024). Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 145(15). 1658–1669. 1 indexed citations

Fu, Weijun, Soo‐Mee Bang, Honghui Huang, et al.. (2024). Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. 104(1). 515–525. 2 indexed citations

Anderson, Larry D., Alfred Chung, Chakra P. Chaulagain, et al.. (2024). Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups. Blood. 144(Supplement 1). 675–675. 1 indexed citations

Rajkumar, S. Vincent, María‐Victoria Mateos, Xiwu Lin, et al.. (2024). Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database. Blood Cancer Journal. 14(1). 215–215.

Hungria, Vânia, Paulo Rodinei Soares Lopes, Fabio Moore Nucci, et al.. (2024). P-340 Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S230–S230.

Fu, Weijun, Soo‐Mee Bang, Honghui Huang, et al.. (2023). Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study. Blood. 142(Supplement 1). 3388–3388. 1 indexed citations

Tervonen, Tommi, Annette Lam, Katharine S. Gries, et al.. (2023). Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma. Value in Health. 26(6). 909–917. 6 indexed citations

10.

Dimopoulos, Meletios Α., Peter M. Voorhees, Hartmut Goldschmidt, et al.. (2022). Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.. Journal of Clinical Oncology. 40(16_suppl). TPS8075–TPS8075. 4 indexed citations

11.

Spencer, Andrew, Philippe Moreau, María‐Victoria Mateos, et al.. (2022). Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. Journal of Clinical Oncology. 40(16_suppl). 8052–8052. 4 indexed citations

12.

Hogan, Laura, Teena Bhatla, David T. Teachey, et al.. (2022). Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. Journal of Clinical Oncology. 40(16_suppl). 10001–10001. 19 indexed citations

13.

Mateos, María‐Victoria, Sophie Rigaudeau, Supratik Basu, et al.. (2022). Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma. Journal of Oncology Pharmacy Practice. 29(5). 1172–1177. 10 indexed citations

14.

He, Jianming, et al.. (2021). Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany. Patient. 14(5). 613–623. 10 indexed citations

15.

Cohen, Yaël C., Albert Oriol, Ka Lung Wu, et al.. (2020). Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(1). 46–54.e4. 12 indexed citations

16.

Luo, Man, Saad Z. Usmani, María‐Victoria Mateos, et al.. (2020). Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. The Journal of Clinical Pharmacology. 61(5). 614–627. 12 indexed citations

17.

Donk, Niels W.C.J. van de, Sonja Zweegman, Jesús F. San Miguel, et al.. (2020). Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM). Blood. 136(Supplement 1). 10–11. 6 indexed citations

18.

Fujisaki, Tomoaki, Takayuki Ishikawa, Hiroyuki Takamatsu, et al.. (2019). Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. Annals of Hematology. 98(12). 2805–2814. 7 indexed citations

19.

Sonneveld, Pieter, Annemiek Broijl, Francesca Gay, et al.. (2019). Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. Journal of Clinical Oncology. 37(15_suppl). TPS8055–TPS8055. 31 indexed citations

20.

Aroua, Nesrine, Jean‐Emmanuel Sarry, Fabienne de Toni, et al.. (2015). In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells. Blood. 126(23). 4269–4269. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact